# Sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine

> **NCT05373030** · PHASE4 · UNKNOWN · sponsor: **Zhejiang Provincial Center for Disease Control and Prevention** · enrollment: 200 (estimated)

## Conditions studied

- Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization

## Interventions

- **BIOLOGICAL:** Recombinant adenovirus type-5-vectored COVID-19 vaccine

## Key facts

- **NCT ID:** NCT05373030
- **Lead sponsor:** Zhejiang Provincial Center for Disease Control and Prevention
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-14
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05373030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05373030, "Sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT05373030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*